Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | PREP | P48147 | 3/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7112036 | 1.00 | PNMT (0.42) | PNMTSMN1; SMN2ALDH1A1PARP1PREP | |
| SCHEMBL30762653 | 0.94 | ALDH1A1 (0.49) | SMN1; SMN2ALDH1A1PREPRAB9A | |
| SCHEMBL5690458 | 0.94 | ALDH1A1 (0.49) | SMN1; SMN2ALDH1A1PREPRAB9A | |
| SCHEMBL29074159 | 0.90 | PREP (0.48) | SMN1; SMN2ALDH1A1PREPRAB9A | |
| SCHEMBL28510227 | 0.90 | PREP (0.48) | SMN1; SMN2ALDH1A1PREPRAB9A | |
| SCHEMBL28885250 | 0.86 | CD274 (0.41) | PNMTPARP1PREPDRD2DRD4 | |
| SCHEMBL28885251 | 0.86 | CD274 (0.41) | PNMTPARP1PREPDRD2DRD4 | |
| SCHEMBL28885318 | 0.85 | SMN1; SMN2 (0.44) | SMN1; SMN2PARP1NPC1RAB9APTGDR2 | |
| Cysteine SCHEMBL28072401 | 0.84 | CTRB1 (0.43) | SMN1; SMN2ALDH1A1PREPRAB9A | |
| SCHEMBL14750393 | 0.84 | PREP (0.44) | PNMTPARP1PREPDRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6528503-B2 | Anticoagulants | MERCK & CO., INC. | 2003-03-04 | — | — | US | disclosed |
| US-20030013700-A1 | Thrombin inhibitors | MERCK SHARP & DOHME CORP. | 2003-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013700-A1 | Thrombin inhibitors | TFPI, PLAT, TFPI2 | PNMT 2492/4885SMN1; SMN2 3710/4885ALDH1A1 2961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.